Omeros (OMER) Starts Planned Pharmacokinetic Substudy In OMS302 Phase 3 Program
- 9:45 AM — May 31 —
- Source: iStockAnalyst
(By Balaseshan) Omeros Corp. (NASDAQ: OMER ), a clinical-stage biopharmaceutical company, said it has started the planned pharmacokinetic substudy in its Phase 3 clinical program evaluating OMS302 in patients undergoing intraocular lens replacement (ILR) surgery. Read More
Advertisement
Om
Biography
The sparingly named Om reunites the oft-heralded Sleep rhythm section of Al Cisneros (bass, vocals) and Chris Haikus (drums);... Read the full Om bio.
Om
Exclusives
Om



